Cardio Diagnostics Stock (NASDAQ:CDIO)

Revenue Ownership Financials Chart

Previous Close

$1.27

52W Range

$0.97 - $20.34

50D Avg

$2.40

200D Avg

$3.85

Market Cap

$2.17M

Avg Vol (3M)

$431.31K

Beta

2.87

Div Yield

-

CDIO Company Profile

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Jan 14, 2022

Website

CDIO Performance

Revenue Breakdown

Revenue Breakdown by Product/Service

Product/Service	Mar 25
Reportable Segments	$940.00

Fiscal year ends in Dec 24 | Currency in USD

CDIO Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	$2.02K	$17.07K	$950.00
Operating Income	$-8.38M	$-7.24M	$-4.55M
Net Income	-	$-8.38M	$-4.66M
EBITDA	-	$-1.53M	$-4.64M
Basic EPS	-	$-0.66	$-1.51
Diluted EPS	-	$-0.66	$-1.51

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
RADX	Radiopharm Theranostics Limited
CELZ	Creative Medical Technology Holdings, Inc.
ADXN	Addex Therapeutics Ltd
NRSN	NeuroSense Therapeutics Ltd.
ADIL	Adial Pharmaceuticals, Inc.
BCLI	Brainstorm Cell Therapeutics Inc.
BCDA	BioCardia, Inc.
TCRT	Alaunos Therapeutics, Inc.